The Future of Immune Health and Chronic Inflammation Management

Dr. Charles Akle, a leading surgeon and immunologist, faced a heartbreaking challenge when his son was diagnosed with a chronic illness caused by Epstein-Barr Virus (EBV). Despite top medical care, his son’s condition—driven by chronic inflammation—left him bedridden for over a decade. Determined to find a solution, Dr. Akle’s research led him to the discovery of Mycolicibacterium obuense, a non-pathogenic bacterium with powerful immune-regulating properties. This breakthrough became the foundation for immy, a revolutionary immunobiotic designed to reduce chronic inflammation and restore immune balance.

Unlike traditional probiotics, immy works by training the immune system to regulate itself, addressing the root cause of chronic inflammation that fuels many diseases, such as cancer, autoimmune disorders, and neurodegenerative conditions. With over $100 million and two decades of research backing it, immy is the first scientifically validated, non-toxic oral supplement that uses Mycolicibacterium aurum Aogashima (MAA) to help your body fight the harmful effects of systemic inflammation.

By targeting the immune system at its core, immy supports long-term health, reduces stress, boosts energy, and enhances resilience—making it an essential part of daily wellness. Explore how immy can help transform your immune health and regain your vitality.

The information provided here is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. This does not replace advice from a physician or medical professional. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.